Biomarkers for Risk Stratification in Patients with Previously Untreated Follicular Lymphoma Receiving Anti-CD20-Based Biologic Therapy
      QxMD      Google Scholar   
Citation:
Am J Surg Pathol vol 45 (3) 384-93
Year:
2021
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Meta-Analysis
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
10
Parents:
2393  
Children:
None
Program:
TRP
Primary Committee:
Correl Sci NOS
Sec. Committees:
   
Pharmas:
from Celgene (CALGB 50803), GlaxoSmithKline (CALGB 50901)  
Grants:
U10CA180821, U10CA180882, U24CA196171, UG1CA233180, UG1CA233329, UG1CA233339  
Corr. Author:
 
Authors:
                             
Networks:
CAPITAL, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NY158, NY018   
Study
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-50402, CALGB-50701, CALGB-50803, CALGB-50901
Phases:
2
Keywords: